Skip to main content

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Terminated · Phase 1 · NCT06540066

Conditions: Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor

At a glance

Research payments reported, 2025
$300,126
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
35

About the trial

Sponsor
BeiGene
Tested
BGB-B3227 (drug), Tislelizumab (drug), Chemotherapy (drug)
Dates
Started 2024-09-11; completion 2026-01-09
Results posted
Not yet

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended dose(s) for expansion (RDFE\[s\]) of BGB-B3227 administered alone and in combination with tislelizumab.

From ClinicalTrials.gov, last updated 2026-03-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines USA, Inc. reported $300,126 in research payments for this study in 2025 (49 payments).

Products named: Tevimbra

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.